SCHEMBL3307112

SCHEMBL3307112

CC(C)(C)OC(=O)NCc1ccc(CNC=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.52
NAMPT P43490 2/20 0.50
GAA P10253 1/20 0.50
CA1 P00915 2/20 0.47
CA2 P00918 1/20 0.47
HDAC1 Q13547 2/20 0.46
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH7 P40394 1/20 0.44
MAPT P10636 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4A O75164 1/20 0.44
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
SDCBP O00560 1/20 0.43
SDC2 P34741 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3180689 0.88 L3MBTL1 (0.61) L3MBTL1NAMPTGAACA1CA2
SCHEMBL3307235 0.88 GLS (0.52) L3MBTL1NAMPTCA1HDAC1ADH1B
SCHEMBL694492 0.86 L3MBTL1 (0.53) L3MBTL1NAMPTGAACA1CA2
SCHEMBL6370655 0.85 L3MBTL1 (0.50) L3MBTL1NAMPTGAACA1CA2
SCHEMBL20119968 0.85 NAMPT (0.54) L3MBTL1NAMPTGAACA1CA2
SCHEMBL208544 0.84 EPHX2 (0.57) L3MBTL1NAMPTGAACA1CA2
SCHEMBL1164796 0.82 L3MBTL1 (0.56) L3MBTL1NAMPTGAACA1CA2
SCHEMBL5796279 0.82 L3MBTL1 (0.56) L3MBTL1NAMPTGAACA1CA2
SCHEMBL15259134 0.82 L3MBTL1 (0.56) L3MBTL1NAMPTGAACA1CA2
SCHEMBL12685839 0.82 L3MBTL1 (0.56) L3MBTL1NAMPTGAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099676-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 SHIONOGI & CO., LTD. (JP) 2010-04-22 US disclosed
EP-2128134-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 Shionogi&Co., Ltd. (JP) 2009-12-02 EP disclosed
WO-2005027856-A2 INHIBITORS OF ANTHRAX LETHAL FACTOR CENGENT THERAPEUTICS (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099676-A1 SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13 MMP13, MMP3, MMP26 L3MBTL1 1343/4885NAMPT 3068/4885GAA 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.